Vioquest Pharmaceuticals! Biotec-Flop oder Cancer

Beobachte diesen Titel schon länger, kann mir aber so recht noch keinen Reim darauf machen. Der Kurs ist im vergangenen Jahr deutlich gefallen, die Ergebnisse waren auch eher negativ. Jetzt schlägt der Kurs einige Kapriolen, und das nur bei der Meldung, dass der Verlust 2006 grösser als 2005 war, da man intensiver geforscht hätte.

Sind dies nur die letzten Zuckungen oder Eintagsfliegen oder ist der Wert vor einer völligen Neubewertung?

Ich wäre an Sachmeldungen sehr interessiert und stelle Euch hier eine Meldung aus stockhouse.com rein:

BASKING RIDGE, N.J., Nov 21, 2006 /PRNewswire-FirstCall via COMTEX News Network/ --
VioQuest Pharmaceuticals, Inc. (OTC Bulletin Board: VQPH), a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, reported a loss from continuing operations of $911,000, or $0.02 per share, for the third quarter ended September 30, 2006, compared to a loss from continuing operations of $774,000, or $0.04 per share, for the same quarter of 2005. For the nine months ended September 30, 2006, the loss from continuing operations was $3.2 million or $0.08 per share, compared to a loss from continuing operations of $1.7 million or $0.10 per share, for the same period of 2005. The loss includes non-cash employee stock option charges of approximately $165,000 and $590,000 for the three and nine months ended September 30, 2006, respectively.

The loss was primarily attributed to higher research and development expenses as the Company advanced its clinical development programs, in addition to increased selling, general and administrative expenses. VioQuest expects to continue to incur losses associated with increased expenses from further advancing its clinical programs and expansion of its corporate infrastructure.

The Company made significant progress in the third quarter, achieving several key milestones.

-- VioQuest initiated dosing of first patients in two separate trials:
VQD-002, triciribine phosphate (TCN-P), at MD Anderson Cancer Center
for treatment of leukemia; and VQD-001, sodium stibogluconate (SSG),
also at MD Anderson, for evaluation of solid tumors.
-- Subsequent to the third quarter's end, VioQuest completed a $4.0
million financing. In addition, the Company is exploring strategic
alternatives for its Chiral Quest business, including a possible sale
of that business. As a result, the Chiral Quest business has been
treated as discontinued operations in the interim financial statements
for the third quarter.


Daniel Greenleaf, VioQuest's President and CEO, said, "We are very pleased with the progress we have made this quarter. We are particularly excited about the development progress we are making with VQD-002 and we believe that VQD-002 is the only compound in clinical development that is a specific inhibitor of phosphorylated Akt. Also known as protein kinase B, Akt is hyper-phosphorylated (and thereby over activated) in a high percentage of leukemia tumors and a wide range of solid tumors, including breast, ovarian, colorectal and pancreatic cancers that appear to be addicted to this enzyme."

About VioQuest Pharmaceuticals, Inc.

VioQuest Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in clinic trials: VQD-001, an inhibitor of specific protein tyrosine phosphatases, has shown compelling preclinical activity in both renal and melanoma cancers and VQD-002 which inhibits the phosphorylation of Akt which can be seen in abnormal levels in breast, ovarian, colorectal, pancreatic, and liquid cancers. VioQuest's subsidiary Chiral Quest, Inc., a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug.


Und jetzt hoffentlich zahlreiche Postings!!!!   Danke


 

VioQuest Pharmaceuticals, Inc. acquires, develops, and commercializes targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. A pioneer in personalized therapeutics, VioQuest has two targeted therapeutics in clinical trials: VQD-001, an inhibitor of specific protein tyrosine phosphatases, has shown compelling preclinical activity in both renal and melanoma cancers and VQD-002 which has shown to inhibit the phosphorylation of Akt which can be seen in abnormal levels in breast, ovarian, colorectal, pancreatic, and hematologic malignancies.

VioQuest’s subsidiary, Chiral Quest, a leader in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug.